Misconduct in science
Anel Potti, Joseph Nevins and their colleagues at Duke University in Durham, North Carolina, garnered widespread attention in 2006. They reported in the New England Journal of Medicine that they could predict the course of a patient's lung cancer using devices called expression arrays, which log the activity patterns of thousands of genes in a sample of tissue as a colourful picture. A few months later, they wrote in Nature Medicine that they had developed a similar technique which used gene expression in laboratory cultures of cancer cells, known as cell lines, to predict which chemotherapy would be most effective for an individual patient suffering from lung, breast or ovarian cancer. At the time, this work looked like a tremendous advance for personalised medicine--the idea that understanding the molecular specifics of an individual's illness will lead to a tailored treatment.
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Top-Ranked MA Plans Earn Their Stars
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- Ebola: Health Officials Try to Quell Front Line Fears
- Defensive Medicine Still Prevalent Despite Tort Reform
- How Hospitals Can Become 'Upstreamists'
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening
- 4 Tips for Managing Employed Physicians